Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024)
基于证据的专家共识:布鲁顿酪氨酸激酶抑制剂的临床安全性管理(2024)
期刊:Chinese Journal of Cancer Research
影响因子:6.3
doi:10.21147/j.issn.1000-9604.2024.03.02
Song, Zaiwei; Jiang, Dan; Yu, Lingling; Chen, Yixuan; Zhou, Daobin; Li, Yue; Wu, Depei; Zhang, Lingli; Miao, Liyan; Ma, Jun; Zhu, Jun; Jing, Hongmei; Zhao, Rongsheng; Steering Committee, On Behalf Of The; Evidence-Based Pharmacy Professional Committee Of Chinese Pharmaceutical ; Chinese Pharmaceutical Association Cpa, Hospital Pharmacy Professional Committee ; Chinese Pharmacological Society Cps, Division Of Therapeutic Drug Monitoring Of; Clinical Oncology Csco, Expert Committee On Lymphoma Of Chinese Society Of; Chinese Society Of Clinical Oncology Csco, Expert Committee On Leukemia Of; China Anti-Cancer Association Caca, Society Of Integrative Cardio-Oncology Of; Chinese Medical Association Cma, Chinese Society Of Hematology Of; Cross-Straits Medicine Exchange Association Smea, Hospital Pharmacy Professional